

March 2022 Update

The Myhre Syndrome Foundation Patient Registry at CoRDS includes participants from **5 continents** and **13 countries**, including Argentina, Australia, Canada, France, Germany, Israel, Italy, Netherlands, Norway, Spain, United Kingdom and United States.



sample size: 67

Of the registry participants:

61% Female
39% Male



sample size: 62

Age of Diagnosis:

0-5: 45.1%
6-10: 29.4%
11-20: 19.6%
21-30: 2.0%
31+: 3.9%



sample size: 51


55% of registry participants reported having one or more **heart conditions**. Of those responding:

- 56% have “arterial stenosis” (nonspecific term)
- 50% have hypertension
- 47% have a congenital heart defect
- 6% have cardiomyopathy
- 3% have pericardial disease



sample size: 58

People with Myhre Syndrome reported the following **skeletal features/abnormalities**:

- | | | |
|-----------------------------|---|----------------------------------|
| 88% short stature |  | 25% webbing of hands and/or feet |
| 82% limited range of motion | | 14% thick calvarium |
| 71% small hands and feet | | 10% scoliosis |
| 57% brachydactyly | | 10% fused vertebrae |
| 39% shortened long bones | | 6% hemivertebrae |

sample size: 51

57% of registry participants reported **respiratory conditions** including:

- Asthma
- Larynx and/or tracheal stenosis
- Obstructive sleep apnea
- “Restrictive pulmonary disease” (nonspecific term)
- Subglottic stenosis



sample size: 56

Myhre syndrome is caused by a change in the SMAD4 gene. Of the respondents that knew their **gene variant**:

- 51.4% had Ile500Val
- 31.4% had Arg496Cys
- 11.4% had Ile500Thr
- 5.7% had Ile500Met



sample size: 35

Almost 2/3rds of registry participants reported **hearing loss**. Sensorineural, conductive and mixed hearing loss have all been reported in people with Myhre Syndrome.



sample size: 55

Thank you to all registry participants!
To learn more, go to:
www.myhresyndrome.org/patient-registry



Myhre Syndrome Foundation Patient Registry at CoRDS

March 2022 Update

Participants from:

5 continents

13 countries, including
Argentina, Australia,
Canada, France, Germany,
Israel, Italy, Netherlands,
Norway, Spain, United
Kingdom and United States.

sample size: 67



Age of Diagnosis:

0-5: 45.1%

6-10: 29.4%

11-20: 19.6%

21-30: 2.0%

31+: 3.9%

sample size: 51



61% Female
39% Male

sample size: 62



Myhre Syndrome Foundation Patient Registry at CoRDS

March 2022 Update



Myhre syndrome is caused by a change in the SMAD4 gene. There are four gene changes or variants that have been reported. Of the respondents that knew their variant:

- 51.4% had Ile500Val
- 31.4% had Arg496Cys
- 11.4% had Ile500Thr
- 5.7% had Ile500Met

Sample size: 35




Myhre Syndrome Foundation Patient Registry at CoRDS

March 2022 Update

HEART CONDITIONS

55% of registry participants reported having a cardiovascular condition



Of those reporting cardiovascular conditions-

- 56% have “arterial stenosis” (nonspecific term)
- 50% have hypertension
- 47% have a congenital heart defect
- 6% have cardiomyopathy
- 3% have pericardial disease


sample size: 58



Myhre Syndrome Foundation Patient Registry at CoRDS

March 2022 Update

People with Myhre Syndrome reported the following skeletal features/abnormalities:



sample size: 51



Myhre Syndrome Foundation Patient Registry at CoRDS

March 2022 Update



57% of registry participants reported respiratory conditions including-

- Asthma
- Larynx and/or tracheal stenosis
- Obstructive sleep apnea
- “Restrictive pulmonary disease” (nonspecific term)
- Subglottic stenosis

sample size: 56



Myhre Syndrome Foundation Patient Registry at CoRDS

March 2022 Update

Almost 2/3rds of registry participants reported **hearing loss.**

Sensorineural, conductive and mixed hearing loss have all been reported.



sample size: 55